PE20110106A1 - Peptidos mediadores del eflujo del colesterol mejorados - Google Patents

Peptidos mediadores del eflujo del colesterol mejorados

Info

Publication number
PE20110106A1
PE20110106A1 PE2010001150A PE2010001150A PE20110106A1 PE 20110106 A1 PE20110106 A1 PE 20110106A1 PE 2010001150 A PE2010001150 A PE 2010001150A PE 2010001150 A PE2010001150 A PE 2010001150A PE 20110106 A1 PE20110106 A1 PE 20110106A1
Authority
PE
Peru
Prior art keywords
cholesterol efflux
mediator
peptides
polypeptide
refers
Prior art date
Application number
PE2010001150A
Other languages
English (en)
Spanish (es)
Inventor
John K Bielicki
Jan Johansson
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of PE20110106A1 publication Critical patent/PE20110106A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2010001150A 2008-06-18 2009-06-17 Peptidos mediadores del eflujo del colesterol mejorados PE20110106A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7370808P 2008-06-18 2008-06-18

Publications (1)

Publication Number Publication Date
PE20110106A1 true PE20110106A1 (es) 2011-03-02

Family

ID=41434685

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010001150A PE20110106A1 (es) 2008-06-18 2009-06-17 Peptidos mediadores del eflujo del colesterol mejorados

Country Status (14)

Country Link
US (1) US8415293B2 (cg-RX-API-DMAC10.html)
EP (1) EP2300038A4 (cg-RX-API-DMAC10.html)
JP (1) JP2011525181A (cg-RX-API-DMAC10.html)
KR (1) KR20110043597A (cg-RX-API-DMAC10.html)
CN (1) CN102123722A (cg-RX-API-DMAC10.html)
AU (1) AU2009260024A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0915422A2 (cg-RX-API-DMAC10.html)
CA (1) CA2727465A1 (cg-RX-API-DMAC10.html)
CL (1) CL2010001445A1 (cg-RX-API-DMAC10.html)
IL (1) IL209868A0 (cg-RX-API-DMAC10.html)
MX (1) MX2010014003A (cg-RX-API-DMAC10.html)
PE (1) PE20110106A1 (cg-RX-API-DMAC10.html)
RU (1) RU2011101536A (cg-RX-API-DMAC10.html)
WO (1) WO2009155366A2 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130123173A1 (en) * 2010-04-28 2013-05-16 The Regents Of The University Of California Creation of oxidation-resistant hdl mimetic peptides
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
RU2016144908A (ru) 2014-05-02 2018-06-05 Серени Терапеутикс Холдинг Са Маркеры hdl-терапии
WO2016044177A1 (en) * 2014-09-17 2016-03-24 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
US10532105B2 (en) * 2015-07-10 2020-01-14 Peptinovo Biopharma, LLC. Formulations for improving the efficacy of hydrophobic drugs
US11840707B2 (en) 2016-05-31 2023-12-12 Institut De Cardiologie De Montreal Co-culture system and method for in vitro assessment of reverse cholesterol transport
CN110294791B (zh) * 2019-06-13 2023-02-21 倪京满 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用
CN111848742B (zh) * 2020-07-23 2021-03-23 南京医科大学 一种多肽及其制药用途
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备
CN115300609B (zh) * 2021-05-08 2026-07-28 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1706131A4 (en) 2003-12-15 2009-08-12 Univ California THE CELLULAR CHOLESTEROL EFFLUX STIMULATING HELICULAR SYNTHETIC PEPTIDES
ATE533783T1 (de) 2006-12-13 2011-12-15 Univ California Potente und selektive mittlersubstanzen von cholesterolefflux

Also Published As

Publication number Publication date
EP2300038A2 (en) 2011-03-30
CL2010001445A1 (es) 2012-03-16
WO2009155366A2 (en) 2009-12-23
RU2011101536A (ru) 2012-07-27
IL209868A0 (en) 2011-02-28
CA2727465A1 (en) 2009-12-23
CN102123722A (zh) 2011-07-13
WO2009155366A3 (en) 2010-04-22
JP2011525181A (ja) 2011-09-15
AU2009260024A1 (en) 2009-12-23
EP2300038A4 (en) 2013-09-04
MX2010014003A (es) 2011-02-15
KR20110043597A (ko) 2011-04-27
US20110190196A1 (en) 2011-08-04
BRPI0915422A2 (pt) 2017-06-27
US8415293B2 (en) 2013-04-09

Similar Documents

Publication Publication Date Title
PE20110891A1 (es) Vacuna de peptido ch3 de ige
AR082805A1 (es) PEPTIDO O COMPLEJO PEPTIDICO QUE SE UNE A INTEGRINA a2 Y METODOS Y USOS QUE IMPLICAN A LOS MISMOS
EA033386B1 (ru) Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
ES2673556T3 (es) Vacunas para el VHS-2
PE20121393A1 (es) Analogo peptidico de oxintomodulina
NZ591612A (en) Prevention, treatment and diagnosis of p.gingivalis infection with peptides
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
PE20110394A1 (es) Virus sincitial respiratorio vivo atenuado
MX336715B (es) Purificacion de iduronato-2-sulfatasa.
NZ598356A (en) Antigenic tau peptides and uses thereof
PE20081723A1 (es) Vacuna contra el papilomavirus
PE20130648A1 (es) Tratamiento del sindrome de sanfilippo tipo b
EA202090053A2 (ru) Способы и композиции для лечения неэффективного эритропоэза
PE20120021A1 (es) Mutantes fgf21
UA107329C2 (uk) Туберкульозний білок rv2386c, композиція, що його містить, та застосування
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
PE20090483A1 (es) Vectores para la expresion multiple de genes
MX2011012906A (es) Produccion recombinante de peptidos.
MX344015B (es) Vacunas y diagnostico para torque teno virus porcino.
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
CY1118856T1 (el) Εμβολιο pcsk9
PE20142167A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados
EP2589658A4 (en) PARTICLE POLYPEPTIDE OF THE REIC / DKK-3 PROTEIN
JP2012102105A5 (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal